FDA Warning To Skin Care Firm Shows Perils Of Cosmetics-To-OTC Transition
This article was originally published in The Tan Sheet
Executive Summary
FDA's warning letter saying skin care product firm MW Laboratories marketed unapproved new drugs illustrates the potentially perilous transition from offering cosmeceuticals to marketing OTC drugs
You may also be interested in...
Data Leave Holes In Cosmeceutical Vitamin Claims - Study
Researchers say their literature review shows gaps in the data supporting topical vitamins' prevention and treatment of skin aging
Cosmeceutical Claims May Be Headed Into FDA's Radar
FDA under the Obama administration may cast a sharper eye on cosmeceuticals than the agency has in years past, according to Georgia C. Ravitz, a food and drug law lawyer at Arent Fox
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.